CoChat

Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018

Open access
Lee, Byungkyu, Zhao, Wanying, Yang, Kai-Cheng, Ahn, Yong-Yeol, Perry, Brea L. · 2021 · JAMA Network Open
Cited by 184

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Importance: In response to the increase in opioid overdose deaths in the United States, many states recently have implemented supply-controlling and harm-reduction policy measures. To date, an updated policy evaluation that considers the full policy landscape has not been conducted. Objective: To evaluate 6 US state-level drug policies to ascertain whether they are associated with a reduction in indicators of prescription opioid abuse, the prevalence of opioid use disorder and overdose, the prescription of medication-assisted treatment (MAT), and drug overdose deaths. Design, Setting, and Participants: This cross-sectional study used drug overdose mortality data from 50 states obtained from the National Vital Statistics System and claims data from 23 million commercially insured patients in the US between 2007 and 2018. Difference-in-differences analysis using panel matching was conducted to evaluate the prevalence of indicators of prescription opioid abuse, opioid use disorder and overdose diagnosis, the prescription of MAT, and drug overdose deaths before and after implementation of 6 state-level policies targeting the opioid epidemic. A random-effects meta-analysis model was used to summarize associations over time for each policy and outcome pair. The data analysis was conducted July 12, 2020. Exposures: State-level drug policy changes to address the increase of opioid-related overdose deaths included prescription drug monitoring program (PDMP) access, mandatory PDMPs, pain clinic laws, prescription limit laws, naloxone access laws, and Good Samaritan laws. Main Outcomes and Measures: The outcomes of interests were quarterly state-level mortality from drug overdoses, known indicators for prescription opioid abuse and doctor shopping, MAT, and prevalence of drug overdose and opioid use disorder. Results: This cross-sectional study of drug overdose mortality data and insurance claims data from 23 million commercially insured patients (12 582 378 female patients [55.1%]; mean [SD] age, 45.9 [19.9] years) in the US between 2007 and 2018 found that mandatory PDMPs were associated with decreases in the proportion of patients taking opioids (-0.729%; 95% CI, -1.011% to -0.447%), with overlapping opioid claims (-0.027%; 95% CI, -0.038% to -0.017%), with daily morphine milligram equivalent greater than 90 (-0.095%; 95% CI, -0.150% to -0.041%), and who engaged in drug seeking (-0.002%; 95% CI, -0.003% to -0.001%). The proportion of patients receiving MAT increased after the enactment of mandatory PDMPs (0.015%; 95% CI, 0.002% to 0.028%), pain clinic laws (0.013%, 95% CI, 0.005%-0.021%), and prescription limit laws (0.034%, 95% CI, 0.020% to 0.049%). Mandatory PDMPs were associated with a decrease in the number of overdose deaths due to natural opioids (-518.5 [95% CI, -728.5 to -308.5] per 300 million people) and methadone (-122.7 [95% CI, -207.5 to -37.8] per 300 million people). Prescription drug monitoring program access policies showed similar results, although these policies were also associated with increases in overdose deaths due to synthetic opioids (380.3 [95% CI, 149.6-610.8] per 300 million people) and cocaine (103.7 [95% CI, 28.0-179.5] per 300 million people). Except for the negative association between prescription limit laws and synthetic opioid deaths (-723.9 [95% CI, -1419.7 to -28.1] per 300 million people), other policies were associated with increasing overdose deaths, especially those attributed to non-prescription opioids such as synthetic opioids and heroin. This includes a positive association between naloxone access laws and the number of deaths attributed to synthetic opioids (1338.2 [95% CI, 662.5 to 2014.0] per 300 million people). Conclusions and Relevance: Although this study found that existing state policies were associated with reduced misuse of prescription opioids, they may have the unintended consequence of motivating those with opioid use disorders to access the illicit drug market, potentially increasing overdose mortality. This finding suggests that there is no easy policy solution to reverse the epidemic of opioid dependence and mortality in the US.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2020.36687

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. Compton, 2016, Relationship between nonmedical prescription-opioid use and heroin use., N Engl J Med, 374, 154, 10.1056/NEJMra1508490 · DOI · Paper page
  2. Pauly, 2018, Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings., Drug Alcohol Depend, 184, 26, 10.1016/j.drugalcdep.2017.12.002 · DOI · Paper page
  3. Meara, 2016, State legal restrictions and prescription-opioid use among disabled adults., N Engl J Med, 375, 44, 10.1056/NEJMsa1514387 · DOI · Paper page
  4. Nam, 2017, State prescription drug monitoring programs and fatal drug overdoses., Am J Manag Care, 23, 297
  5. Paulozzi, 2011, Prescription drug monitoring programs and death rates from drug overdose., Pain Med, 12, 747, 10.1111/j.1526-4637.2011.01062.x · DOI · Paper page
  6. Buchmueller, 2018, The effect of prescription drug monitoring programs on opioid utilization in Medicare., Am Econ J Econ Policy, 10, 77, 10.1257/pol.20160094 · DOI · Paper page
  7. Meinhofer, 2018, Prescription drug monitoring programs: the role of asymmetric information on drug availability and abuse., Am J Health Econ, 4, 504, 10.1162/ajhe_a_00101 · DOI
  8. Abouk, 2019, Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose., JAMA Intern Med, 179, 805, 10.1001/jamainternmed.2019.0272 · DOI · Paper page
  9. Rees, 2019, With a little help from my friends: the effects of good Samaritan and naloxone access laws on opioid-related deaths., J Law Econ, 62, 1, 10.1086/700703 · DOI · Paper page
  10. Fink, 2018, Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review., Ann Intern Med, 168, 783, 10.7326/M17-3074 · DOI · Paper page
  11. Finley, 2017, Evaluating the impact of prescription drug monitoring program implementation: a scoping review., BMC Health Serv Res, 17, 420, 10.1186/s12913-017-2354-5 · DOI · Paper page
  12. Kiang, 2020, Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study., BMJ, 368, l6968, 10.1136/bmj.l6968 · DOI · Paper page
  13. Perry, 2019, Co-prescription network reveals social dynamics of opioid doctor shopping., PLoS One, 14, 10.1371/journal.pone.0223849 · DOI
  14. Wallace, 2014, Optum Labs: building a novel node in the learning health care system., Health Aff (Millwood), 33, 1187, 10.1377/hlthaff.2014.0038 · DOI · Paper page
  15. Katz, 2010, Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006., Pharmacoepidemiol Drug Saf, 19, 115, 10.1002/pds.v19:2 · doi:10.1002/pds.v19:2
  16. Bobashev, 2018, Polydrug use among heroin users in Cleveland, OH., Drug Alcohol Depend, 192, 80, 10.1016/j.drugalcdep.2018.06.039 · DOI
  17. Jones, 2015, Vital signs: demographic and substance use trends among heroin users—United States, 2002-2013., MMWR Morb Mortal Wkly Rep, 64, 719
  18. Viechtbauer, 2010, Conducting meta-analyses in R with the metafor package., J Stat Softw, 36, 1, 10.18637/jss.v036.i03 · DOI · Paper page
  19. Dart, 2015, Trends in opioid analgesic abuse and mortality in the United States., N Engl J Med, 372, 241, 10.1056/NEJMsa1406143 · DOI · Paper page
  20. Jalal, 2018, Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016., Science, 361, 10.1126/science.aau1184 · DOI · Paper page
  21. Karamouzian, 2018, A public health approach to opioid addiction in North America., Lancet, 391, 201, 10.1016/S0140-6736(18)30057-6 · DOI
  22. Lyapustina, 2016, Effect of a “pill mill” law on opioid prescribing and utilization: the case of Texas., Drug Alcohol Depend, 159, 190, 10.1016/j.drugalcdep.2015.12.025 · DOI
  23. Rutkow, 2015, Effect of Florida’s prescription drug monitoring program and pill mill laws on opioid prescribing and use., JAMA Intern Med, 175, 1642, 10.1001/jamainternmed.2015.3931 · DOI · Paper page
  24. Sohn, 2019, Association of naloxone coprescription laws with naloxone prescription dispensing in the United States., JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.6215 · DOI
  25. Follman, 2019, Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose., JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.3209 · DOI
  26. Swartz, 2019, Prescription opioid availability and opioid overdose-related mortality rates in Medicaid expansion and non-expansion states., Addiction, 114, 2016, 10.1111/add.v114.11 · doi:10.1111/add.v114.11
  27. Wen, 2020, Association between Medicaid expansion and rates of opioid-related hospital use., JAMA Intern Med, 180, 753, 10.1001/jamainternmed.2020.0473 · DOI
  28. Webster, 2011, Obtaining adequate data to determine causes of opioid-related overdose deaths., Pain Med, 12, S86, 10.1111/j.1526-4637.2011.01132.x · DOI
  29. Alpert, 2018, Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids., Am Econ J Econ Policy, 10, 1, 10.1257/pol.20170082 · DOI · Paper page
  30. Mallatt? J. The effect of prescription drug monitoring programs on opioid prescriptions and heroin crime rates.? SSRN. Preprint posted online September 13, 2018. doi:10.2139/ssrn.3050692 · DOI
  31. Doleac? JL, Mukherjee? A. The moral hazard of lifesaving innovations: naloxone access, opioid abuse, and crime.? SSRN. Preprint posted online March 31, 2019. doi:10.2139/ssrn.3135264 · DOI
  32. Sacks? DW, Hollingsworth? A, Nguyen? TD, Simon? KI. Can policy affect initiation of addictive substance use? evidence from opioid prescribing? evidence from opioid prescribing. National Bureau of Economic Research working paper 25974. June 2019. Accessed January 6, 2020. https://www.nber.org/system/files/working_papers/w25974/w25974.pdf · DOI
  33. Pohl? RV. Time trends matter: the case of medical cannabis laws and opioid overdose mortality.? SSRN. Preprint posted online November 21, 2019. · DOI

Cited by

See all 184

Metadata

Authors
Lee, B., Zhao, W., Yang, K.-C., Ahn, Y.-Y., & Perry, B. L.
Venue
JAMA Network Open
Published
2021-02-12
Volume
4
Issue
2
Pages
e2036687
ISSN
2574-3805 (ISSN-L)
OpenAlex
W3126362147
Cited by
184
References
7
FWCI
27.55
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.